Clinical trials: Diabete Mellitus
Dietary Habits
Low-carbohydrate Versus Low-fat Breakfast in Type 2 Diabetes
The prevalence of type 2 diabetes (T2D) is increasing worldwide, with ~380 M currently suffering from this chronic, debilitating disease. T2D is characterized by high blood glucose levels in the mornings and after meals.
- Trial name
- NCT04550468
- Testing
- Low-Carb High-Fat breakfast, Low fat "standard care" control breakfast
- Where
- Canada
- Volunteers
- 127 people
- Sponsor
- University of British Columbia
Type 2 Diabetes Mellitus
Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus
To compare the change in glycemic control from baseline to endpoint (last available posttreatment assessment) as measured by HbA1c in pediatric subjects with type 2 diabetes receiving either glimepiride or metformin as…
- Trial name
- NCT00353691
- Testing
- glimepiride, metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sanofi
Self Care
Evaluation of the Eversense Continuous Glucose Monitoring System in Type I Diabetic Youth
The purpose of this clinical investigation is to provide pilot clinical data to direct pivotal study development for the pediatric indication of the Senseonics Continuous Glucose Monitoring System (CGM) measurements when compared…
- Trial name
- FNH (NCT03815552)
- Testing
- Eversense Continuous Glucose Monitoring
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Kinderkrankenhaus auf der Bult
Diabetes Type 1
Transition of T1DM Patients Aged Over 65 Years Into AHCL (780G) Insulin Pump
Older people with diabetes have a higher risk for cognitive impairment and for physical disability whether this may be effected by an improvement in glucose indices is unknown.
- Trial name
- 780G65+ (NCT06207838)
- Testing
- MiniMed 780G system
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Jagiellonian University
Healthy Volunteers
Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food
The purpose of this study is to assess the effect of coadministration of a high-fat meal on the oral bioavailability of a fixed dose combination of Canagliflozin/extended release Metformin (CANA/MET XR) tablet, containing 150 mg…
- Trial name
- NCT02039258
- Testing
- CANA/MET XR FDC
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 1
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
Type 1 diabetes is an autoimmune disease characterized by destruction of pancreatic beta-cells, resulting in absolute deficiency of insulin. Presently there is no known cure.
- Trial name
- NCT03182426
- Testing
- Plerixafor, Alemtuzumab, Anakinra
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Alberta
Type 2 Diabetes Mellitus, Coronary Artery Disease
Aspirin Dosing in Diabetic Patients
Since diabetic platelets are characterized by an enhanced turnover rate, it may be hypothesized that an increase in the frequency, rather than the dose, of drug administration may be a more effective strategy to inhibit platelet…
- Trial name
- NCT01201785
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Xerostomia Due to Hyposecretion of Salivary Gland, Diabetes Mellitus, Type 2
The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II
In diabetes Type II the xerostomia is a quite frequent symptom. In evaluating the activity of an artificial saliva spray compared to a water gel in patients with Diabetes Type II patients had to follow a three day treatment with…
- Trial name
- NCT03452085
- Testing
- artificial saliva spray (AS), maritime throat spray (TT)
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Certmedica International GmbH
Obesity, Weight Reduction
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without…
- Conditions
- Obesity, Weight Reduction, Cardiometabolic Risk Factors
- Trial name
- NCT07513168
- Testing
- Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Asian Institute Of Medical Sciences
Obesity, Overweight
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT07030868
- Testing
- LY3549492
- Where
- 42 sites in United States, Argentina
- Volunteers
- 1 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus
The primary purpose of this Study is to help answer the following research question(s). How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes? How does…
- Trial name
- NCT01215968
- Testing
- LY2189265
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus).
- Trial name
- NCT02796950
- Testing
- Acipimox
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
Liver Fibrosis Assessment in Diabetic Patients
The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the…
- Trial name
- NCT06694974
- Testing
- APP calculation for FIB-4, Standard Care (in control arm)
- Where
- Taiwan
- Volunteers
- 540 people
- Sponsor
- National Taiwan University Hospital
Type 1 Diabetes Mellitus
Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study Patients
TELFIT is a monocenter, controlled, randomised trial. It focuses on type 1 diabetes patients that have attended a functional insulin therapy training course.
- Trial name
- TELFIT (NCT00758082)
- Testing
- paper support, PDA-phone + telemonitoring
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Grenoble
Type 2 Diabetes
A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
This is a Phase 1 study, involving a 1-day dosing period, designed to test the safety of investigational study drug ARRY-403 in patients with Type 2 diabetes. Approximately 36 patients from the US will be enrolled in this study.
- Trial name
- NCT00859755
- Testing
- ARRY-403, glucokinase activator; oral
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Array BioPharma
Diabetes, Diabetes Mellitus, Type 2
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes…
- Trial name
- BEGIN™ (NCT01326026)
- Testing
- insulin degludec
- Where
- 45 sites in United States, Finland and 2 more
- Volunteers
- 222 people
- Sponsor
- Novo Nordisk A/S
Cognitive Impairment
The Effects of DPPIs on Cognitive Function of Diabetic Patients
This is a single-center, randomized controlled clinical trial with a parallel-group design conducted at Minia University hospital.
- Trial name
- NCT06164535
- Testing
- Control group, DPP-4 inhibitor group, DPP-4 inhibitor + metformin group
- Where
- Egypt
- Volunteers
- 105 people
- Sponsor
- Beni-Suef University
Diabetes Mellitus, Type 2, Implant Complication
Posterior Narrow Diameter Implants in Hyperglycemic and Normo-glycemic Patients
The aim of the present study was to compare the initial healing and long term performance of narrow diameter implants in patients with uncontrolled Diabetes mellitus type 2 (T2DM) and healthy individuals.
- Trial name
- NCT04630691
- Testing
- Implantation
- Volunteers
- 35 people
- Sponsor
- University of Witten/Herdecke
Healthy, Diabetes Type 2
Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.
The ASI Non-Invasive Arterial Stiffness Screening Device (ASI Device) is an investigational device under development for the non-invasive assessment of arterial stiffness.
- Conditions
- Healthy, Diabetes Type 2, Obesity, Coronary Artery Disease
- Trial name
- ASI-2012 (NCT01722474)
- Testing
- ASI Device
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Motivational Interviewing, Type 1 Diabetes
The Effect of Motivational Interviewing in Children With Type 1 Diabetes
This research was conducted in a randomized controlled experimental way to determine the effect of motivational interviewing on hypoglycemia fear, caregiving, fatigue and self-compassion in parents of children with Type 1…
- Conditions
- Motivational Interviewing, Type 1 Diabetes, Hypoglycemia, Fatigue
- Trial name
- NCT06424574
- Testing
- motivational interview
- Where
- Turkey (Türkiye)
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Yuzuncu Yil University